| 股票 | 标签 | 富途行业 | PE | PB | 股息率 | 分红率 | 毛利率 | ROE | 固定资产 | 负债率 | OCF/市值 | 营收增速 | 利润增速 | 近60日 | YTD | 近一年 | 距52周高 | 市值亿 ▴ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicus Pharma MDCX | 亏损或困境 | 一般药品制造商 | -0.1 | -6.14 | 0.0% | — | — | -3083% | — | 100% | -269.8% | +0% | -218% | -46% | -89% | -92% | 6% | 0 |
| MIRA Pharmaceuticals MIRA | 亏损或困境 | 一般药品制造商 | -0.6 | 3.94 | 0.0% | — | — | -508% | — | 6% | -14.5% | +0% | -33% | -22% | -49% | -45% | 31% | 0 |
| Nasus Pharma NSRX | 亏损或困境 | 一般药品制造商 | -5.7 | 15.83 | 0.0% | — | — | 0% | — | 45% | -24.1% | +0% | -282% | +23% | -59% | -53% | 39% | 0 |
| Scilex Holding SCLX | 亏损或困境 | 一般药品制造商 | -0.1 | -0.15 | 0.0% | — | 65% | 0% | 4% | 158% | -37.1% | -46% | -414% | -1% | -29% | -61% | 25% | 0 |
| 阿玛琳 AMRN | 亏损或困境 | 一般药品制造商 | -11.4 | 0.65 | 0.0% | — | 57% | -8% | 1% | 32% | 5.4% | -6% | +53% | -8% | -2% | -8% | 65% | 3 |
| Organon & Co OGN | 定价权·品牌 | 一般药品制造商 | 17.7 | 3.60 | 0.6% | 10% | 53% | 31% | 9% | 94% | 20.4% | -3% | -78% | +3% | +93% | +33% | 100% | 36 |
| 基立福 GRFS | 中性 | 一般药品制造商 | 10.2 | 0.82 | 3.6% | 36% | 38% | 7% | 17% | 61% | 23.9% | +18% | +165% | +8% | -16% | -22% | 77% | 53 |
| 渤健公司 BIIB | 轻资产现金牛 | 一般药品制造商 | 39.2 | 1.73 | 0.0% | 0% | 76% | 7% | 11% | 38% | 8.8% | +2% | -21% | +14% | +26% | +56% | 98% | 326 |
| 葛兰素史克 GSK | 定价权·品牌 | 一般药品制造商 | 15.7 | 4.19 | 3.6% | 56% | 72% | 38% | 17% | 74% | 11.1% | +12% | +129% | -2% | +4% | +29% | 83% | 1000 |
| 赛诺菲安万特 SNY | 成长兑现 | 一般药品制造商 | 23.3 | 1.32 | 5.3% | 124% | 72% | 10% | 10% | 43% | 13.0% | +19% | +58% | +2% | -4% | -0% | 89% | 1060 |
| 施贵宝 BMY | 定价权·品牌 | 一般药品制造商 | 14.7 | 6.12 | 3.8% | 55% | 71% | 40% | 8% | 79% | 9.4% | -0% | +179% | +22% | +28% | +50% | 97% | 1365 |
| 辉瑞 PFE | 轻资产现金牛 | 一般药品制造商 | 37.4 | 1.90 | 6.0% | 226% | 74% | 9% | 8% | 58% | 8.3% | -2% | -3% | +13% | +20% | +24% | 97% | 1622 |
| 吉利德科学 GILD | 定价权·品牌 | 一般药品制造商 | -57.0 | 15.83 | 2.1% | — | 79% | 40% | 7% | 62% | 7.2% | +2% | +1673% | +25% | +24% | +34% | 97% | 1872 |
| 诺和诺德 NVO | 定价权·品牌 | 一般药品制造商 | 11.4 | 6.05 | 3.8% | 44% | 81% | 61% | 24% | 64% | 4.0% | +20% | +14% | +10% | -4% | -10% | 76% | 2081 |
| 安进 AMGN | 定价权·品牌 | 一般药品制造商 | 27.2 | 20.22 | 2.2% | 61% | 67% | 106% | 10% | 90% | 5.3% | +10% | +88% | +30% | +36% | +60% | 98% | 2364 |
| 阿斯利康 AZN | 定价权·品牌 | 一般药品制造商 | 24.4 | 5.02 | 1.9% | 47% | 82% | 21% | 10% | 57% | 5.4% | +9% | +45% | -8% | -10% | +2% | 78% | 2523 |
| 诺华制药 NVS | 定价权·品牌 | 一般药品制造商 | 24.2 | 7.32 | 3.0% | 72% | 76% | 31% | 11% | 58% | 6.0% | +10% | +17% | +8% | +20% | +28% | 97% | 3041 |
| 默沙东 MRK | 定价权·品牌 | 一般药品制造商 | 120.3 | 8.85 | 2.2% | 269% | 75% | 37% | 18% | 62% | 5.4% | +1% | +7% | +27% | +45% | +85% | 96% | 3709 |
| 艾伯维公司 ABBV | 定价权·品牌 | 一般药品制造商 | 72.4 | -76.35 | 2.6% | 191% | 70% | 15222% | 5% | 102% | 4.3% | +9% | -1% | +15% | +15% | +26% | 96% | 4532 |
| 强生 JNJ | 定价权·品牌 | 一般药品制造商 | 31.9 | 7.80 | 1.9% | 61% | 68% | 35% | 14% | 59% | 4.2% | +6% | +91% | +16% | +35% | +58% | 98% | 6633 |
| 礼来 LLY | 成长兑现 | 一般药品制造商 | 38.6 | 31.93 | 0.6% | 22% | 83% | 101% | 17% | 76% | 2.6% | +45% | +95% | +1% | +8% | +57% | 89% | 10820 |
点表头排序。市值单位亿美元;财务为最近年报(futu 筛选器);分红率 = 股息率 × PE;OCF/市值 = 经营现金流 ÷ 市值(无 FCF);距52周高 = 现价 / 52 周最高。